Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2334
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients ; volume:17 ; number:1 ; day:16 ; month:3 ; year:2017 ; pages:1-7 ; date:12.2017
BMC infectious diseases ; 17, Heft 1 (16.3.2017), 1-7, 12.2017
- Keyword
-
Krebs
Onkologie
- Creator
-
Maggiolo, Franco
- Contributor
-
Gulminetti, Roberto
Pagnucco, Layla
Digaetano, Margherita
Benatti, Simone
Valenti, Daniela
Callegaro, Annapaola
Ripamonti, Diego
Mussini, Cristina
SpringerLink (Online service)
- DOI
-
10.1186/s12879-017-2311-2
- URN
-
urn:nbn:de:1111-201704062889
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Maggiolo, Franco
- Gulminetti, Roberto
- Pagnucco, Layla
- Digaetano, Margherita
- Benatti, Simone
- Valenti, Daniela
- Callegaro, Annapaola
- Ripamonti, Diego
- Mussini, Cristina
- SpringerLink (Online service)
Other Objects (12)
Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
Persistent platelet activation and apoptosis in virologically suppressed HIV-infected individuals
Dolutegravir-based anti-retroviral therapy is effective and safe in HIV–infected paediatric patients
Virologically suppressed switch to Dolutegravir/Lamivudine 2-Drug regimen versus switch to commonly prescribed 3-Drug regimens in the United States
Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
Sex-related differences in markers of immune activation in virologically suppressed HIV-infected patients
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
Abacavir/lamivudine has shown similar efficacy to other nucleoside conventional combinations in previously HIV-infected patients: results at 48 weeks
Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies
Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice
HIV lamivudine resistance mutations in HBV co-infected Romanian patients
HIV-1 pretreatment and acquired antiretroviral drug resistance before tenofovir/ lamivudine /dolutegravir (TLD) roll-out in Mozambique
Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
Persistent platelet activation and apoptosis in virologically suppressed HIV-infected individuals
Dolutegravir-based anti-retroviral therapy is effective and safe in HIV–infected paediatric patients
Virologically suppressed switch to Dolutegravir/Lamivudine 2-Drug regimen versus switch to commonly prescribed 3-Drug regimens in the United States
Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
Sex-related differences in markers of immune activation in virologically suppressed HIV-infected patients
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
Abacavir/lamivudine has shown similar efficacy to other nucleoside conventional combinations in previously HIV-infected patients: results at 48 weeks
Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies
Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice
HIV lamivudine resistance mutations in HBV co-infected Romanian patients
HIV-1 pretreatment and acquired antiretroviral drug resistance before tenofovir/ lamivudine /dolutegravir (TLD) roll-out in Mozambique
Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
Persistent platelet activation and apoptosis in virologically suppressed HIV-infected individuals
Dolutegravir-based anti-retroviral therapy is effective and safe in HIV–infected paediatric patients
Virologically suppressed switch to Dolutegravir/Lamivudine 2-Drug regimen versus switch to commonly prescribed 3-Drug regimens in the United States
Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
Sex-related differences in markers of immune activation in virologically suppressed HIV-infected patients
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
Abacavir/lamivudine has shown similar efficacy to other nucleoside conventional combinations in previously HIV-infected patients: results at 48 weeks
Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies
Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice
HIV lamivudine resistance mutations in HBV co-infected Romanian patients